- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Sanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of $316.59 in 2027 | 1 | Seeking Alpha | ||
| 07.08. | Sanuwave Q2 2026 slides: consumables rise as system sales slide | 1 | Investing.com | ||
| 07.08. | SANUWAVE Health GAAP EPS of -$0.08, revenue of $9.74M | 1 | Seeking Alpha | ||
| SANUWAVE HEALTH Aktie jetzt für 0€ handeln | |||||
| 06.08. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | SANUWAVE Health, Inc.: Sanuwave Announces Q2 FY2026 Financial Results | 152 | GlobeNewswire (Europe) | Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026... ► Artikel lesen | |
| 06.08. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.07. | Sanuwave sees Q2 revenue up to $9.8M | 1 | Seeking Alpha | ||
| 13.07. | Sanuwave: Q2-Umsatz übertrifft Prognose | 3 | Investing.com Deutsch | ||
| 13.07. | Sanuwave posts Q2 revenue of $9.6M-$9.8M, beating guidance | 1 | Investing.com | ||
| 13.07. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | SANUWAVE Health, Inc.: Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance | 1.032 | GlobeNewswire (Europe) | EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced... ► Artikel lesen | |
| 16.06. | SANUWAVE Health, Inc.: Sanuwave Health Updates Second Quarter 2026 Guidance | 248 | GlobeNewswire (Europe) | Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June... ► Artikel lesen | |
| 15.06. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Sanuwave forecasts Q2 revenue of $11.1M-$11.6M while maintaining $51M-$55M full-year outlook | 1 | Seeking Alpha | ||
| 13.05. | SANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 13.05. | SANUWAVE Health reports mixed Q1 results; initiates Q2 and reaffirms FY26 outlook | 2 | Seeking Alpha | ||
| 12.05. | SANUWAVE Health, Inc.: Sanuwave Announces Revenues and Financial Results for Q1 FY2026 | 241 | GlobeNewswire (Europe) | Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.... ► Artikel lesen | |
| 12.05. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.04. | Sanuwave Health (SNWV) Slipped as CMS Dropped the Coverage Limit | 1 | Insider Monkey |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,460 | -0,36 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,068 | +5,26 % | Sernova Biotherapeutics Inc: Sernova shareholder Sangha to vote "yes" in takeover | ||
| CERENOME | 1,744 | -0,57 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | +5,10 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 0,970 | +2,57 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,395 | -0,62 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,030 | -1,82 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| CLOVER HEALTH INVESTMENTS | 3,920 | +1,03 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 7,850 | -5,99 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,965 | -0,35 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen | |
| NANO-X IMAGING | 0,745 | +1,54 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMUNON | 1,220 | 0,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
SANUWAVE HEALTH INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,075 (-1,65 %) liegt der Kurs bei 4,475 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANUWAVE HEALTH INC finden Sie auf Wallstreet Online.